Clinical Trial Update: A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study of amivantamab, alone or in combination with other agents, for head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 1, Phase 2 | Status: RECRUITING